Governance Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-10 EDT			5-day change	1st Jan Change
3.050 ^USD	-2.24%		-3.48%	-15.51%

07-07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-29	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark	CI

Executive Committee: Altimmune, Inc.

Manager

Positions heldSince

Jerome Durso

58 year

Chief Executive Officer	2025-12-31
President	2025-12-31

Luis Sanay

Investor Relations Contact

2026-02-28

Rachel Garner

Chief Tech/Sci/R&D Officer

2025-04-30

Caroline Fajolle

Human Resources Officer

Robin Abrams

62 year

General Counsel	2025-04-30
Corporate Secretary	2025-04-30

Christophe Arbet-Engels

64 year

Chief Tech/Sci/R&D Officer

2025-09-30

Randy Brown

Chief Tech/Sci/R&D Officer

J. Horton

57 year

General Counsel

Gregory Weaver

70 year

Director of Finance/CFO

2024-11-10

Andrew Shutterly

38 year

Comptroller/Controller/Auditor

2023-01-31

Anthony Blandin

Compliance Officer

2022-01-31

M. Roberts

67 year

Chief Tech/Sci/R&D Officer

2012-11-30

Composition of the Board of Directors: Altimmune, Inc.

Director

CommitteesSince

Jerome Durso

58 year

Chairman

2025-08-11

Wayne Pisano

71 year

Audit Committee
Compensation Committee
Governance Committee Chair	2018-08-29
Nominating Committee Chair	2018-08-29

Catherine Sohn

72 year

Compensation Committee	2011-12-31
Governance Committee	2023-03-22
Nominating Committee	2023-03-22
Compensation Committee Chair

Mack Gill

74 year

Audit Committee	2004-07-31
Governance Committee	2004-07-31
Nominating Committee	2004-07-31

Klaus Schafer

76 year

Audit Committee	2017-05-03
Compensation Committee

Teri Lawver

59 year

Governance Committee	2025-08-11
Nominating Committee	2025-08-11

Philip Hodges

58 year

Compensation Committee	2017-05-03
Audit Committee Chair	2003-08-31

Diane Jorkasky

74 year

Compensation Committee

2020-07-10

Mitchel Sayare

78 year

Audit Committee

2025-08-11

Latest Appointments: Altimmune, Inc.

12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI
12-01	Altimmune CEO Vipin Garg to Step Down	MT
12-01	Altimmune announces CEO transition, succession plan	RE
11-10	Celldex Therapeutics, Inc. Announces Executive Changes	CI
11-06	Altimmune, Inc. Announces Appointment of Robin Abrams, J.D., as Chief Legal Officer	CI
25-09-29	Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025	CI

More news

Former Officers and Directors: Altimmune, Inc.

Insider

Positions held

SinceUntil

Bertrand Georges

Chief Tech/Sci/R&D Officer

2015-02-28

2026-02-28

Vipin K. Garg

Director/Board Member	2018-11-29	2025-12-31
Chief Executive Officer	2018-11-29	2025-12-31
President	2018-11-29	2025-12-31

Raymond Jordt

Corporate Officer/Principal

2022-12-31

2025-12-31

M. Harris

Chief Tech/Sci/R&D Officer

2019-09-08

2025-09-30

Sarah Browne

Chief Tech/Sci/R&D Officer

2025-03-31

David Drutz

Director/Board Member	2017-04-30	2024-09-25
Chairman	2011-09-30	2017-04-30
Independent Dir/Board Member	2009-12-31	2024-09-25

Richard Eisenstadt

Comptroller/Controller/Auditor	2021-12-30	2024-06-26
Director of Finance/CFO	2021-12-30	2024-06-26
Investor Relations Contact	2021-12-30	2024-06-26
Corporate Secretary	2021-12-30	2024-06-26

Dakshina Reddy

General Counsel

2022-03-31

2024-02-29

Kent Tapper

Comptroller/Controller/Auditor

2015-05-31

2023-01-31

Jose Ochoa

Corporate Officer/Principal

2018-07-09

2022-12-31

William Brown

Comptroller/Controller/Auditor	2018-05-07	2021-12-30
Director of Finance/CFO	2018-05-07	2021-12-30
Investor Relations Contact	2018-05-07	2021-12-30
Public Communications Contact	2018-05-07	2021-12-30
Corporate Secretary	2018-05-07	2021-12-30

Karen Smith

Corporate Officer/Principal

2020-08-31

Sybil Tasker

Chief Tech/Sci/R&D Officer

2017-05-03

2019-06-29

William Enright

Director/Board Member	2007-12-31	2018-11-29
Chief Executive Officer	-	2018-11-29
President	-	2018-11-29

Elizabeth Czerepak

Director of Finance/CFO	2015-03-31	2018-05-07
Corporate Secretary	2015-03-31	2018-05-07

Philip MacNeill

Director of Finance/CFO	2015-04-30	2017-05-03
Corporate Secretary	2015-04-30	2017-05-03
Treasurer	2015-04-30	2017-05-03

Derace L. Schaffer

Director/Board Member	2005-03-31	-
Independent Dir/Board Member	2005-03-31	-

Ori Solomon

General Counsel

Stacey L. Jurchison

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	17
Female	5

Of which Executive Committee

Male	9
Female	3

Of which Directors

Male	8
Female	1

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Employees

Sector

Biotechnology & Medical Research

More about the company